URN:NBN:SI:doc-6C4VQUWV2022Aiken Vinkovič, TinaHren, RokRotar-Pavlič, Danicadocuments/doc/6/URN_NBN_SI_doc-6C4VQUWV_001.pdfdocuments/doc/6/URN_NBN_SI_doc-6C4VQUWV_001.txt573articlestr. 351-3630014-8229132799491URN:NBN:SI:doc-6C4VQUWVslvSlovensko farmacevtsko društvoFarmacevtski vestnikInCcost-effectivenessfarmakoekonomikapharmacoeconomicspneumococcal diseasespneumococcal vaccinepnevmokokne boleznipnevmokokno cepivostroškovna učinkovitostCost-effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine in SloveniaStroškovna učinkovitost uporabe 23-valentnega polisaharidnega pnevmokoknega cepiva pri odraslih v Sloveniji